Kenneth Jarvis

The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo.

Joann P. Palma, Luis E. Rodrı́guez, Velitchka Bontcheva-Diaz et al. · PubMed · 2008 · 56 citations

Medicine, Medicinal Chemistry, Pharmacology +14

In-vitro and in-vivo potency of five new fluoroquinolones against anaerobic bacteria

Prabhavathi Fernandes, N. L. Shipkowitz, Robert R. Bower et al. · Journal of Antimicrobial Chemotherapy · 1986 · 41 citations

Medicine, Microbiology, Pharmacology +13

In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones

Prabhavathi Fernandes, D. T. W. CHU, Robert R. Bower et al. · Antimicrobial Agents and Chemotherapy · 1986 · 33 citations · Full text

Medicine, Microbiology, Pharmacology +9

Dietary Supplementation with Fructooligosaccharides Increase Survival Time in a Hamster Model of Clostridium difficile-Colitis

Bryan W. Wolf, Jonathan A. Meulbroek, Kenneth Jarvis et al. · Bioscience and Microflora · 1997 · 27 citations · Full text

Life Sciences, Nutrition, Nutritional Sciences +10

Antitumor Activity of Orally Bioavailable Farnesyltransferase Inhibitor, ABT-100, Is Mediated by Antiproliferative, Proapoptotic, and Antiangiogenic Effects in Xenograft Models

Debra C. Ferguson, Luis E. Rodrı́guez, Joann P. Palma et al. · Clinical Cancer Research · 2005 · 22 citations · Full text

Medicine, Oncology, Pharmacology +16